Get the Stockscreener App
141.31
3.40%
4.64
After Hours:
140.50
-0.81
-0.57%
Illumina Inc stock is traded at $141.31, with a volume of 1.08M.
It is up +3.40% in the last 24 hours and up +3.89% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$136.67
Open:
$137.96
24h Volume:
1.08M
Relative Volume:
0.58
Market Cap:
$22.41B
Revenue:
$4.39B
Net Income/Loss:
$-1.58B
P/E Ratio:
-14.19
EPS:
-9.96
Net Cash Flow:
$546.00M
1W Performance:
+3.54%
1M Performance:
+3.89%
6M Performance:
+23.43%
1Y Performance:
+4.00%
1-Day Range:
$137.59
$141.86
1-Week Range:
$131.75
$141.86
52-Week Range:
$100.08
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
141.31 | 22.41B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Inside the new Illumina MiSeq i100 Series: The making of the software - Illumina
Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Raised by Assenagon Asset Management S.A. - MarketBeat
Genetic Testing Market Projected To Witness Substantial Growth, 2025-2032: Eurofins Scientific, Illumina Inc., - EIN News
Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research - GlobeNewswire Inc.
Illumina, Inc.'s (NASDAQ:ILMN) Price Is Out Of Tune With Revenues - Simply Wall St
Illumina, Inc. (NASDAQ:ILMN) Receives $165.63 Consensus PT from Brokerages - MarketBeat
Microfluidics Market Poised for Substantial Growth (2025-2032) | PerkinElmer, Agilent Technologies, Inc., Illumina. - openPR
Key Trends in the Bioinformatics Market with Insights from - openPR
Sax Wealth Advisors LLC Purchases Shares of 4,198 Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Avanza Fonder AB Buys Shares of 17,599 Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Partners NVIDIA for Genomic Advancements, ILMN Stock Climbs - MSN
JP Morgan 2025: analysts remain doubtful of Illumina’s growth - MSN
Gateway Investment Advisers LLC Raises Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Video: The first NovaSeq X in the Benelux region is a “game changer” - Illumina
Bioinformatics Market Analysis, Size, Share, and Growth - openPR
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Sicart Associates LLC - MarketBeat
Whole Exome Sequencing Market Overall Study Report 2025-2032 | - openPR
Global Single Cell Bioinformatics Software and Service Market - openPR
Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Beech Hill Advisors Inc. Has $1.92 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Short Interest Update - MarketBeat
10,833 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by USA Financial Formulas - MarketBeat
Lab-on-a-chip and Microarrays (Biochip) Market Future - openPR
Biomarker Research Services Market Projected To Witness Substantial Growth, 2025-2032:Abbott Laboratories, - EIN News
Illumina (NASDAQ:ILMN) Trading Up 5.7%Time to Buy? - MarketBeat
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025 - Longview News-Journal
Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by CCLA Investment Management - MarketBeat
Illumina, Nvidia Launch AI-Based Genomics Partnership - Genetic Engineering & Biotechnology News
Future-Proofing Growth of DNA Data Storage Market, Size, - openPR
Molecular Diagnostics Market Size, Share & Business Opportunities forecast by 2031 | F. Hoffmann-La Roche Ltd, - EIN News
RNA Sequencing Market 2024-2031 Global Industry Analysis, - openPR
Illumina CEO Highlights Genomics Future and Nvidia Partnership at JPMorgan Health-Care Conference - HPBL
Genomic Cancer Testing Market Future Business Opportunities - openPR
Illumina partners with Nvidia on AI-powered genomic sequencing - MSN
Illumina reports preliminary Q4 results, provides 2025 expectations - MSN
Illumina CEO Thaysen on Nvidia Partnership, Genomics, M&A - Marketscreener.com
Nvidia Announces Partnerships with Mayo Clinic, Illumina & More at JPM25 - Dealbreaker
Illumina Raises Q4 Revenue Outlook To $1.10 Billion, Exceeding Street Expectations; Sees Solid Margins - Benzinga
Illumina (NASDAQ:ILMN) Issues FY 2024 Earnings Guidance - MarketBeat
Illumina posts modest Q4 revenue growth, anticipates 2025 rise - Investing.com
Illumina (NASDAQ:ILMN) Issues Q4 Earnings Guidance - MarketBeat
Illumina stock falls on 2025 outlook miss By Investing.com - Investing.com Australia
Illumina, Nvidia collaborate to decode biology and propel precision health - Yahoo Finance
Illumina stock falls on 2025 outlook miss - Investing.com
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database - MSN
Nvidia (NVDA) Expands Healthcare Presence with Illumina Partnership - TipRanks
Illumina (NASDAQ:ILMN) Trading 5.7% HigherWhat's Next? - MarketBeat
Illumina partners with NVIDIA for advanced genomics analysis By Investing.com - Investing.com Canada
Morgan Stanley Cuts Illumina (NASDAQ:ILMN) Price Target to $150.00 - MarketBeat
Illumina, Nvidia team to use AI in foundation models - MedTech Dive
Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database - Yahoo Finance
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):